PHARMASGP HOLDING SE PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio

Transparency directive : regulatory news

15/09/2021 18:58

DGAP-Ad-hoc: PharmaSGP Holding SE / Key word(s): Change in Forecast
PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio

15-Sep-2021 / 18:58 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio

Gräfelfing, September 15, 2021 - Following the scheduled closing on August 31, 2021 of the agreement signed with the GlaxoSmithKline Group on the acquisition of an OTC portfolio with the brands Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R) (the "GSK Portfolio"), PharmaSGP Holding SE is adjusting its revenues and earnings guidance for the 2021 financial year. This was decided by the company's Management Board today. Revenues as well as the adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) of the PharmaSGP Group, which replaces the previous performance indicator "adjusted earnings before interest and taxes (adjusted EBIT)", serve as key performance indicators.

Previously, revenues of between € 56 million and € 60 million (2020: € 63.2 million) were expected for fiscal 2021, excluding any acquisitions, with a stable to slightly positive development of the "Health Brands" category and a declining "Beauty" business as expected. For the adjusted EBIT margin, the company had forecast an increase to between 27% and 30% (2020: 26.1 %); this corresponds to an adjusted EBITDA margin of between 28% and 31% (2020: 26.9 %). Including the revenues and earnings contributions of the GSK portfolio from September 1, 2021 onwards, the Management Board now expects full-year 2021 revenues of between € 60 million and € 65 million and an adjusted EBITDA margin of between 27 % and 31 %.

Note: The key performance indicators "Adjusted EBIT" and "Adjusted EBITDA" are not key performance indicators under IFRS. The adjustments used to derive adjusted EBITDA correspond to those used for adjusted EBIT. Information on this is available in the PharmaSGP Holding SE Annual Report 2020 on p. 37 (available at https://ir.pharmasgp.com).
 


15-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: PharmaSGP Holding SE
Lochhamer Schlag 21
82166 Gräfelfing
Germany
E-mail: ir@pharmasgp.com
Internet: https://pharmasgp.com
ISIN: DE000A2P4LJ5
WKN: A2P4LJ
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich
EQS News ID: 1233677

 
End of Announcement DGAP News Service

1233677  15-Sep-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1233677&application_name=news&site_id=symex


Other stories

23/09/2021 06:17
23/09/2021 05:37
22/09/2021 23:29
23/09/2021 00:40
23/09/2021 01:28
22/09/2021 15:28
22/09/2021 17:47
22/09/2021 22:38
22/09/2021 16:47
22/09/2021 21:37
22/09/2021 16:01
23/09/2021 03:14
22/09/2021 21:51
22/09/2021 22:09
22/09/2021 18:01
23/09/2021 06:29
22/09/2021 13:04
22/09/2021 11:58
22/09/2021 18:01
21/09/2021 22:18
21/09/2021 20:19
22/09/2021 15:00
22/09/2021 23:56
23/09/2021 01:51
22/09/2021 14:15
23/09/2021 01:29
22/09/2021 23:43
22/09/2021 21:46
23/09/2021 01:01
22/09/2021 23:35
22/09/2021 17:00
23/09/2021 05:30
21/09/2021 13:22
21/09/2021 12:07
22/09/2021 18:48
22/09/2021 19:01
21/09/2021 08:44
22/09/2021 15:12